Shares of Teladoc Health Inc (NYSE:TDOC) have earned an average rating of “Buy” from the twenty-two brokerages that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation, fifteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $82.95.

Several equities research analysts have weighed in on TDOC shares. Citigroup increased their target price on shares of Teladoc Health to $80.00 and gave the stock a “buy” rating in a report on Thursday, July 19th. Canaccord Genuity reiterated a “buy” rating and issued a $70.00 target price (up from $63.00) on shares of Teladoc Health in a report on Wednesday, July 25th. Robert W. Baird increased their price objective on shares of Teladoc Health from $50.00 to $65.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 25th. Cantor Fitzgerald reissued a “hold” rating and set a $52.00 price objective on shares of Teladoc Health in a research report on Wednesday, August 1st. Finally, Piper Jaffray Companies increased their price objective on shares of Teladoc Health to $77.00 and gave the stock an “overweight” rating in a research report on Thursday, August 2nd.

TDOC traded down $2.84 during mid-day trading on Monday, hitting $62.49. The stock had a trading volume of 1,469,974 shares, compared to its average volume of 2,017,914. The company has a debt-to-equity ratio of 0.40, a quick ratio of 8.99 and a current ratio of 8.99. The firm has a market cap of $4.79 billion, a PE ratio of -37.87 and a beta of 0.96. Teladoc Health has a 1-year low of $27.30 and a 1-year high of $89.05.

Teladoc Health (NYSE:TDOC) last posted its earnings results on Thursday, November 1st. The health services provider reported ($0.34) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.36) by $0.02. The company had revenue of $111.00 million for the quarter, compared to analyst estimates of $109.94 million. Teladoc Health had a negative net margin of 31.32% and a negative return on equity of 14.05%. The business’s revenue for the quarter was up 61.6% compared to the same quarter last year. During the same period last year, the business posted ($0.55) earnings per share. Equities analysts forecast that Teladoc Health will post -1.47 EPS for the current fiscal year.

In related news, SVP Andrew Turitz sold 8,202 shares of the firm’s stock in a transaction on Tuesday, September 4th. The shares were sold at an average price of $77.42, for a total value of $634,998.84. Following the completion of the transaction, the senior vice president now owns 9,378 shares of the company’s stock, valued at $726,044.76. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Mark Hirschhorn sold 35,000 shares of the firm’s stock in a transaction on Tuesday, September 25th. The shares were sold at an average price of $80.42, for a total transaction of $2,814,700.00. Following the completion of the transaction, the vice president now directly owns 10,000 shares of the company’s stock, valued at approximately $804,200. The disclosure for this sale can be found here. In the last ninety days, insiders sold 235,930 shares of company stock valued at $17,033,927. 3.95% of the stock is owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. grew its position in Teladoc Health by 9.0% in the second quarter. BlackRock Inc. now owns 5,318,850 shares of the health services provider’s stock valued at $308,759,000 after purchasing an additional 437,136 shares in the last quarter. Bank of America Corp DE lifted its stake in Teladoc Health by 82.8% in the second quarter. Bank of America Corp DE now owns 1,883,185 shares of the health services provider’s stock valued at $109,318,000 after acquiring an additional 853,076 shares during the last quarter. Zevenbergen Capital Investments LLC lifted its stake in Teladoc Health by 3.9% in the second quarter. Zevenbergen Capital Investments LLC now owns 1,629,170 shares of the health services provider’s stock valued at $94,574,000 after acquiring an additional 61,325 shares during the last quarter. Gilder Gagnon Howe & Co. LLC lifted its stake in Teladoc Health by 1.6% in the third quarter. Gilder Gagnon Howe & Co. LLC now owns 1,501,216 shares of the health services provider’s stock valued at $129,630,000 after acquiring an additional 23,940 shares during the last quarter. Finally, Northern Trust Corp lifted its stake in Teladoc Health by 7.8% in the second quarter. Northern Trust Corp now owns 799,539 shares of the health services provider’s stock valued at $46,414,000 after acquiring an additional 58,189 shares during the last quarter.

Teladoc Health Company Profile

Teladoc Health, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

See Also: Technical Analysis of Stocks, How Can It Help

Analyst Recommendations for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.